1. P2Y2R-Mediated PAK1 Activation Is Involved in ESM-1 Overexpression in RT-R-MDA-MB-231 through FoxO1 Regulation
   Hana Jin et al, 2022, Cancers CrossRef
2. Interleukin-1β and Cancer
   Cédric Rébé et al, 2020, Cancers CrossRef
3. Targeting purinergic pathway to enhance radiotherapy-induced immunogenic cancer cell death
   Xuhui Bao et al, 2022, Journal of Experimental & Clinical Cancer Research CrossRef
4. NLRC4, ASC and Caspase-1 Are Inflammasome Components That Are Mediated by P2Y2R Activation in Breast Cancer Cells
   Hana Jin et al, 2020, International Journal of Molecular Sciences CrossRef
5. ESM-1 Overexpression is Involved in Increased Tumorigenesis of Radiotherapy-Resistant Breast Cancer Cells
   Hana Jin et al, 2020, Cancers CrossRef
6. Cell-type-specific role of P2Y2 receptor in HDM-driven model of allergic airway inflammation
   Dominik Schneble et al, 2023, Frontiers in Immunology CrossRef
7. NLRP3 Inflammasome From Bench to Bedside: New Perspectives for Triple Negative Breast Cancer
   Margherita Sonnessa et al, 2020, Frontiers in Oncology CrossRef
8. Extracellular ATP Mediates Cancer Cell Migration and Invasion Through Increased Expression of Cyclooxygenase 2
   Shilpa Sharma et al, 2021, Frontiers in Pharmacology CrossRef
9. Increased Extracellular Adenosine in Radiotherapy-Resistant Breast Cancer Cells Enhances Tumor Progression through A2AR-Akt-β-Catenin Signaling
   Hana Jin et al, 2021, Cancers CrossRef
10. Signaling Through Purinergic Receptor P2Y2 Enhances Macrophage IL-1β Production
    Gonzalo de la Rosa et al, 2020, International Journal of Molecular Sciences CrossRef
11. Autocrine and paracrine purinergic signaling in the most lethal types of cancer
    M. Reyna-Jeldes et al, 2021, Purinergic Signalling CrossRef
12. Prognostic Value of NLRP3 Inflammasome and TLR4 Expression in Breast Cancer Patients
    Concetta Saponaro et al, 2021, Frontiers in Oncology CrossRef